Key Highlights

  • Merck closed at $130.20 at last closing after a 52-week high of $131.84 on 27 July, up about 59% over 12 months, and reports Q2 results on 4 August.
  • Reported 2026 Earnings are depressed by roughly $6 a share of asset-acquisition charges from the Cidara and Terns deals; underlying gross Margin (81.9% in Q1) and $14.1 billion of trailing free Cash Flow are unaffected.
  • The 2028 Keytruda exclusivity loss still dwarfs the replacement pipeline; Lipfendra, Winrevair, sac-TMT and Keytruda Qlex narrow the gap rather than close it.
  • Shares of Merck & Co. closed at $130.20 at last closing, three sessions after touching a 52-week high of $131.84 on 27 July.

A stock at highs, days before the numbers

Co. (NYSE:MRK). Shares of Merck & Co. closed at $130.20 at last closing, three sessions after touching a 52-week high of $131.84 on 27 July. The company reports second-quarter results on the morning of 4 August, with a call at 9:00 a.m. ET.

The July move had identifiable causes. On 16 July the FDA approved Lipfendra (enlicitide decanoate), the first and only once-daily oral PCSK9 inhibitor cleared in the US to lower LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. In the Phase 3 CORALreef program, the 20 mg tablet cut LDL-C by 56% versus placebo in the broader lipids study and 59% in the HeFH study at week 24.

Priced at $315 a month against roughly $500 to $600 for injectable PCSK9 drugs, it undercuts Repatha and Praluent on both convenience and cost; RBC Capital Markets has modeled about $5 billion in sales by 2034, and Guggenheim maintained a $145 price target after the clearance. A day earlier, partner Kelun-Biotech said a Phase 3 trial of sacituzumab tirumotecan combined with Keytruda met its primary progression-free survival endpoint in first-line PD-L1-negative non-squamous non-small-cell lung cancer, with a positive early trend in overall survival.

The tape stopped behaving like a patent-cliff stock

Over the eight sessions to 31 July the stock climbed from $124.40 to $130.20, roughly 5%, on volumes of six to nine million shares a day, active but not disorderly. Stretch the window and the shift is larger: aggregated market data puts the 52-week price change at about 59%, against a 52-week low of $76.66. Market Capitalization is roughly $322 billion, with Enterprise value near $365 billion.

That is a repricing of sentiment more than of current earnings. For two years the market treated Keytruda's expected loss of US exclusivity in 2028 as an event that would remove roughly half the Revenue base with nothing credible behind it. The 2026 news flow has chipped away at that view.

Half a Business in one molecule

Keytruda remains the axis. Combined Keytruda and Keytruda Qlex sales were $8.0 billion in the first quarter of 2026, up 12% (8% excluding currency), very close to half of the $16.3 billion Merck booked company-wide that quarter. Qlex, the subcutaneous formulation approved in 2025, contributed $128 million in its first full quarter, with management pointing to a permanent J-code effective recently as the gating item for broader adoption. The strategic logic is blunt: subcutaneous administration is protected by different intellectual property than the intravenous product, so every patient converted before 2028 is a patient partially insulated from biosimilar pembrolizumab.

Beneath that sit franchises moving in both directions. Winrevair, for pulmonary arterial hypertension, generated $525 million in the quarter, up 88%, and produced positive Phase 2 CADENCE data in combined post- and pre-capillary pulmonary hypertension with preserved ejection fraction. Animal Health delivered $1.8 billion, up 13%, a genuinely uncorrelated earnings stream. Capvaxive rose 33% to $142 million, Bridion 7% to $472 million, Lynparza 9% to $341 million. Against them, Gardasil fell 19% to $1.07 billion on weak Chinese Demand and the wind-down of Japan's catch-up Immunization program, and Januvia/Janumet dropped 28% to generics.

Accounting noise is hiding the operating picture

Reported earnings this year are close to meaningless without adjustment. Merck booked a roughly $9.0 billion asset-acquisition charge, about $3.62 to $3.65 a share, for the January 2026 completion of its $9.2 billion purchase of Cidara Therapeutics. That produced a first-quarter GAAP loss of $1.72 a share and a non-GAAP loss of $1.28, despite revenue growing 5%. A second charge of about $5.8 billion, or $2.35 a share, lands in the second quarter from the $6.7 billion Terns Pharmaceuticals Acquisition , completed. Consensus for 4 August is therefore a loss of $0.26 a share on revenue of about $16.33 billion, up 3.3% year over year.

Full-year guidance issued in April was $65.8 billion to $67.0 billion of sales and non-GAAP EPS of $5.04 to $5.16, the latter already absorbing the Cidara hit. Underlying profitability is intact: first-quarter non-GAAP gross margin was 81.9%, trailing-twelve-month free cash flow $14.1 billion, against $49.1 billion of Debt and $5.7 billion of cash. Management targets roughly $3 billion of annual Buybacks and has raised the Dividend for 15 consecutive years, now $3.40 a share for a 2.6% Yield .

What the deals actually bought

Cidara brought CD388, a long-acting influenza preventive that in mid-stage testing prevented flu symptoms in roughly three-quarters of recipients over six months, with late-stage interim data expected during 2026. Terns brought TERN-701, an oral allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia. Verona Pharma, bought for $10 billion in 2025, brought Ohtuvayre in COPD. Chief executive Robert Davis told the April call the company continues to look at deals "anywhere in the $1 billion to $15 billion range," concentrated in oncology, immunology and cardiometabolic disease.

The bull case is that this is a bench, not a lottery ticket: Lipfendra approved and priced aggressively into a large chronic market, Winrevair compounding at high double digits, sac-TMT validated in a first-line lung cancer setting where immunotherapy alone underperforms, and Keytruda Qlex converting the installed base into defensible territory. Guidance implies revenue growth in a year carrying two multi-billion-dollar write-offs.

The bear case is arithmetic. Nothing in the pipeline replaces a Keytruda Franchise running at roughly $32 billion annualized by 2028, and the subcutaneous switch protects converted patients rather than the whole base. More than $25 billion has gone on three acquisitions since mid-2025 whose lead Assets are largely unapproved. Gardasil is shrinking. Three Phase 3 studies, LITESPARK-012, KEYNOTE-975 and KEYNOTE-866, missed their primary endpoints in the first quarter alone.

Valuation leaves less margin for error

At $130.20 the stock trades on about 21 times forward earnings, 4.9 times trailing sales and roughly 20 times EV/EBITDA, with a free-cash-flow yield near 4.4%. Trailing P/E of 36 is distorted by the acquisition charges. Available data put Merck's forward multiple at 19.25 against 19.43 for its industry, in line with peers, but well above the roughly 12.8 five-year average at which the shares spent the cliff-anxiety years. The discount is gone; from here the stock needs delivery rather than relief.

The measure of the quarter

Tuesday's release will be read past the headline loss. The numbers that matter are the Qlex sales line as the first proxy for conversion speed, whether Gardasil has stopped deteriorating, Winrevair's trajectory now that Europe and Japan are contributing, and whether the sales and underlying EPS ranges move. A stock at a 52-week high has priced in a good deal of the recovery story; the reporting season now has to substantiate it.

Upcoming Catalysts

  • Q2 2026 results and call, 9:00 a.m. ET. Consensus is a $0.26 loss per share on about $16.33 billion of revenue; watch Keytruda Qlex uptake, Gardasil China and any change to the $65.8–$67.0 billion sales guidance.
  • PDUFA date for Keytruda plus Padcev in cisplatin-eligible muscle-invasive bladder cancer. Follows KEYNOTE-B15, which cut event-free survival risk by 47%.
  • PDUFA date for I-DXd in extensive-stage small cell lung cancer. A second late-stage oncology asset outside pembrolizumab monotherapy.
  • Lipfendra US launch metrics, from Q3 2026. Early scripts and payer coverage will test the $315-a-month positioning against injectable PCSK9 incumbents.
  • CD388 late-stage influenza interim data, expected during 2026. The primary justification for the $9.2 billion Cidara outlay.

Principal Risks

  • Keytruda loss of exclusivity in 2028. US biosimilar entry threatens a franchise that was close to half of first-quarter 2026 revenue; the subcutaneous switch mitigates but does not neutralize it.
  • Acquisition execution. Cidara, Terns and Verona cost over $25 billion combined and rest largely on assets that are not yet approved; a late-stage failure would be costly in both cash and credibility.
  • Gardasil deterioration. Sales fell 19% in the first quarter on Chinese and Japanese demand, and no recovery timeline has been given.
  • Valuation compression. At roughly 21 times forward earnings against a 12.8 five-year average multiple, the shares have limited room for a guidance disappointment.
  • US drug pricing and policy. Medicare negotiation and Tariff policy remain live variables for a portfolio weighted to high-priced specialty products.

Conclusion

Merck closed at $130.20 at last closing after a 52-week high of $131.84 on 27 July, up about 59% over 12 months, and reports Q2 results on 4 August. Set against that: US biosimilar entry threatens a franchise that was close to half of first-quarter 2026 revenue; the subcutaneous switch mitigates but does not neutralize it. The next real test: Q2 2026 results and call, 9:00 a.m. ET. Consensus is a $0.26 loss per share on about $16.33 billion of revenue; watch Keytruda Qlex uptake.

This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.